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Introduction
The burden of multi-drug resistant (MDR) bacteria has increased substantially worldwide1 and 
infections caused by these organisms continue to pose a great challenge to public health systems 
and populations at large. MDR is defined as non-susceptibility to at least one agent in three or 
more antimicrobial categories.2 MDR bacterial infections are among the top three threats to global 
public health. Due to the lack of surveillance programmes, the true extent of antimicrobial 
resistance in the African region is unknown or underestimated. Additionally there is no formal 
framework for collaboration among surveillance programmes in the region.1 A request was made 
to the World Health Organization (WHO) by member states in 2017 to develop a global priority 
pathogen list (PPL) of antibiotic-resistant bacteria to help in prioritising the research and 
development of new and effective antibiotic treatments.3 Due to the high prevalence of multi-
drug resistance among ESKAPE bacteria, defined by the Infectious Diseases Society of America as 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp., these pathogens feature prominently in the global 
PPL of antibiotic-resistant bacteria and are the focus of this article. Members of the ESKAPE group 
of bacteria ‘escape’ the biocidal action of antibiotics and present new paradigms in pathogenesis, 
transmission and resistance of infectious diseases.4 ESKAPE pathogens with multiple drug 
resistance mechanisms have been implicated in life-threatening nosocomial infections, especially 
among critically ill individuals,5 presenting clinicians with serious therapeutic challenges.5 
The global PPL stratifies bacterial pathogens into three priority tiers: critical, high and medium.3 
Carbapenem-resistant A. baumannii, P. aeruginosa and Enterobacteriaceae spp., which includes 
Background: To combat antimicrobial resistance, the World Health Organization developed a 
global priority pathogen list of antibiotic-resistant bacteria for prioritisation of research and 
development of new, effective antibiotics. 
Objective: This study describes a five-year resistance trend analysis of the ESKAPE pathogens: 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter spp., from Kwazulu-Natal, South Africa.
Methods: This retrospective study used National Health Laboratory Services data on 64 502 
ESKAPE organisms isolated between 2011 and 2015. Susceptibility trends were ascertained 
from minimum inhibitory concentrations and interpreted using Clinical and Laboratory 
Standards Institute guidelines.
Results: S. aureus was most frequently isolated (n = 24, 495, 38%), followed by K. pneumoniae 
(n = 14, 282, 22%). Decreasing rates of methicillin-resistant S. aureus (28% to 18%, p < 0.001) and 
increasing rates of extended spectrum beta-lactamase producing K. pneumoniae (54% to 65% 
p < 0.001) were observed. Carbapenem resistance among K. pneumoniae and Enterobacter spp. 
was less than 6% during 2011–2014, but increased from 4% in 2014 to 16% in 2015 ( p < 0.001) 
among K. pneumoniae. P. aeruginosa increased ( p = 0.002), but resistance to anti-pseudomonal 
antimicrobials decreased from 2013 to 2015. High rates of multi-drug resistance were observed 
in A. baumanni (> 70%).
Conclusion: This study describes the magnitude of antimicrobial resistance in KwaZulu-Natal 
and provides a South African perspective on antimicrobial resistance in the global priority 
pathogen list, signalling the need for initiation or enhancement of antimicrobial stewardship 
and infection control measures locally.
Antibiotic resistance trends of ESKAPE pathogens 
in Kwazulu-Natal, South Africa: A five-year 
retrospective analysis
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K. pneumoniae, feature in the critical priority tier. Methicillin-
resistant, vancomycin intermediate and resistant S. aureus, in 
addition to E. faecium, are featured in the high priority tier. 
The ESKAPE group of bacteria deserve special attention due 
to their association with antibiotic resistance,6 as infections 
caused by this particular group of pathogens result in high 
mortality and morbidity rates, increased healthcare costs, 
diagnostic dilemma and difficulty in the initiation of 
empirical treatment.7 As a control measure to decrease the 
incidence of infections due to ESKAPE pathogens, site-by-
site surveillance studies and antibiograms are necessary to 
inform effective empiric therapy.8 This study assessed trends 
in annual resistance rates for all ESKAPE pathogens 
processed over a five-year period from 2011 through to 2015 
in KwaZulu-Natal, South Africa.
Evidence before this study
Pathogen surveillance and antimicrobial resistance surveillance 
informs effective antimicrobial prescribing, in addition to 
controlling the spread of resistant pathogens within the local 
environment. It is well known that dedicated surveillance 
systems form an integral strategy to combat antibiotic 
resistance; however, surveillance of antibiotic-resistant 
bacteria is severely lacking in most African countries. The 
largest antimicrobial resistance surveillance data set from 
sub-Saharan Africa was published in 2017 and reflected 
antimicrobial resistance trends from isolates implicated in 
bloodstream infections from adults and children in Malawi 
over a 19-year period were described.9 There have been no 
long-term surveillance data reports describing ESKAPE 
pathogens and their antimicrobial resistance patterns from 
KwaZulu-Natal, South Africa, except for national sentinel 
site surveillance describing antimicrobial resistance among 
K. pneumoniae isolates from bloodstream infections from 
2009–2012. Hence, this study aimed at providing a description 
of ESKAPE pathogens and their antibiotic resistance trends 
over a five-year period in the province of KwaZulu-Natal, 
South Africa.
Added value of this study
The ESKAPE group of bacteria are among the critical and 
high priority pathogens on the global PPL. This study 
provides the largest data set of the ESKAPE pathogens 
gathered from adults and children who presented to the 
largest public service hospitals in KwaZulu-Natal, South 
Africa, over a five-year period. The surveillance data 
provided in this manuscript provide a good baseline 
surveillance intervention to combat antimicrobial 
resistance.
Implications of all the available evidence in 
this study
The WHO global PPL identifies priority pathogens for the 
research and development of new antibiotics. Knowledge of 
these pathogens and their resistance patterns in local 
contexts is pivotal in our fight against antimicrobial 
resistance. Despite a decreasing trend in methicillin-
resistant S. aureus (MRSA), there is emergence and rapid 
expansion of extended spectrum beta-lactamase (ESBL)-
producing K. pneumoniae coupled with fluoroquinolone 
resistance observed in this study. Additionally, increasing 
resistance to third-generation cephalosporins and 
amoxicillin-clavulanate is a growing concern, as there is 
now a greater reliance on the carbapenems to treat infections 
caused by K. pneumoniae. Increasing resistance to 
carbapenems observed in K. pneumoniae is slowly becoming 
a reality in KwaZulu-Natal and may spell the beginning of 
the end for carbapenems against Enterobacteriaceae such as 
K. pneumoniae. Continued surveillance will provide valuable 
information on antimicrobial resistance patterns for 
ESKAPE pathogens, which will assist in informing empiric 
antimicrobial therapy.
Methods
Ethical considerations
This study was approved by the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal (study 
approval number: BE085/12).
Study sites
Data collected from August 2011 to December 2015 at nine 
participating public sector hospitals from two districts 
across the province of KwaZulu-Natal were utilised in this 
study. The nine participating hospitals are the largest in the 
province and represent all levels of healthcare as described 
in Tables 1 and 2.10
Bacterial samples
Each participating centre extracted data of all isolates 
categorised as ESKAPE pathogens. All body sites were 
considered acceptable sources. Samples submitted for 
microbiological analysis included blood, urine, catheters 
(central venous catheter + hemodialysis) and respiratory 
specimens, in addition to samples from other body sites. Not 
every patient who presented to a healthcare facility with an 
infection submitted a sample for microbiological analysis. 
Additionally, the data presented included organisms from all 
specimen types; hence, colonisation was not distinguished 
from infection.
TABLE 1: Public hospitals and bed numbers in KwaZulu-Natal, South Africa.
Hospital Level of healthcare Number of beds
Prince Mshiyeni Memorial Hospital Level 2 Regional 1200
Edendale Hospital Level 2 Regional 874
Inkosi Albert Luthuli Central Hospital Level 4 Central 846
King Edward VIII Hospital Level 3 Tertiary 799
Addington Hospital Level 2 Regional 571
R K Khan Hospital Level 2 Regional 543
Greys Hospital Level 3 Tertiary 530
Northdale Hospital Level 1 District 385
Mahathma Gandhi Memorial Hospital Level 2 Regional 355
Source: Health K-NDo. Provincial Hospitals: KwaZulu-Natal Department of Health. 2014 
[cited 2018 Jan 15]. Available from: http://www.kznhealth.gov.za/hospitals.htm10
Page 3 of 8 Original Research
http://www.ajlmonline.org Open Access
Antimicrobial susceptibility testing
All participating laboratories in this study subscribed to the 
National Health Laboratories Services (NHLS) Proficiency 
Testing Scheme. Evaluations are carried out quarterly and 
samples for the scheme are prepared with assistance from 
the National Institute for Communicable Diseases – Centre 
for Opportunistic, Tropical and Hospital Infections, a 
division of the NHLS. Thus, all laboratories participating in 
this study were proficient in testing bacterial samples. All 
participating laboratories were responsible for sample 
processing, including isolate identification and 
susceptibility testing. Pathogen identification was 
determined using the Vitek 2 (bioMerieux, Marcy l’Étoile, 
France) platform. Antimicrobial susceptibility testing and 
minimum inhibitory concentration determinations were 
performed using the Vitek 2 (bioMerieux, Marcy l’Étoile, 
France) platform. The results were interpreted according to 
the criteria of the Clinical Laboratory Standards Institute.11 
The antimicrobial test panel included: penicillin, ampicillin, 
amoxicillin-clavulanate, ceftriaxone, cefepime, cefuroxime, 
cefoxitin, ceftazadime, imipenem, meropenem, ertapenem, 
piperacillin-tazobactam, amikacin, gentamicin, erythromycin, 
clindamycin, linezolid, teicoplanin, vancomycin, fusidic 
acid, mupirocin, tetracycline, oxacillin, rifampicin, 
nitrofurantoin, colistin, trimethoprim/sulfamethoxazole, 
ciprofloxacin and tigecycline. Methicillin resistance in 
S aureus was inferred by oxacillin resistance.11 The Vitek 2 
AST-N255 card was used to perform antimicrobial 
susceptibility testing on Gram-negative, whereas the 
AST-P603 card was used for Gram-positive organisms. 
Presumptive ESBL production in K. pneumoniae was 
determined using the minimum inhibitory concentration for 
ceftriaxone and ceftazidime as per the Clinical Laboratory 
Standards Institute guidelines.11 Isolates were characterised 
as susceptible or resistant using Clinical Laboratory 
Standards Institute-approved breakpoints.11
Data extraction and analysis
All information regarding specimen collection, sampling and 
patient laboratory results is deposited on the NHLS 
laboratory database. The use of this database and access to 
patient information is restricted to laboratory staff working 
within the NHLS. Thus, data collection was done at the 
NHLS and entailed extraction of isolate information from 
this computerised laboratory database. The data received 
were de-duplicated, anonymised and patient confidentiality 
was maintained at all times. Isolate information, specimen 
type and results of antimicrobial susceptibility testing, 
including minimum inhibitory concentration data, were also 
extracted. Once the data were extracted, trends in the total 
number of ESKAPE pathogens and their antimicrobial 
resistance patterns were determined. These trends were 
compared over a five-year period.
Statistical analysis
All data processing and analyses were performed using Stata 
13.0 software SE (StataCorp. LP, 2013, College Station, Texas, 
United States). Categorical data were presented using 
stratified frequency tables (n and %). Trends or associations 
were assessed using the standard Pearson’s chi-square (χ2) 
test. If expected cell count in the cross tabulation contained 
fewer than five observations (sparse numbers), then the 
Fisher’s exact test was utilised instead. A p-value of less than 
0.05 was considered statistically significant.
Results
Distribution of species by clinical specimens
For the period 2011–2015, a total of 64 502 ESKAPE clinical 
isolates were recovered from clinical specimens (Figure 1). 
The distribution of the isolated ESKAPE organisms varied 
during this period. The clinical specimens included 
respiratory specimens, blood, urine, catheters, which included 
central venous  and hemodialysis catheters, as well as samples 
from other sites, including wounds. Respiratory samples 
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FIGURE 1: Trends in the number of ESKAPE pathogens isolated from clinical 
samples collected in public sector healthcare facilities in KwaZulu-Natal from 
2011 to 2015.
TABLE 2: Levels of healthcare in KwaZulu-Natal, South Africa.
Level Healthcare facility 
1 Primary healthcare clinic: Primary healthcare clinics are the first point in the 
provision of healthcare. Services such as immunisation, family planning, 
antenatal care, treatment of tuberculosis, HIV/AIDS counselling, and 
treatment for common conditions among others are offered here.10
Community healthcare centre: Community healthcare centres offer similar 
services to a primary healthcare clinic with the addition of a 24 h maternity 
service, emergency care and casualty and a short stay ward.10
District hospital: These hospitals receive referrals from and provide 
generalist support to community health centres and clinics. Diagnostic, 
clinical and counselling services are provided. Clinical services provided 
include: casualty, internal medicine, paediatrics, surgery, obstetrics and 
gynaecology, out-patients, mental health, geriatrics and clinical forensic 
medical services.10
2 Regional hospital: These are the second level of healthcare. Regional 
hospitals receive referrals from and provide specialist support to a number of 
district hospitals.10
3 Provincial tertiary hospital: These hospitals receive referrals from and 
provide sub-specialist support to regional hospitals and are the third level of 
healthcare. Provincial tertiary hospitals are staffed by specialists and 
generalists and offer services such as neurosurgery, neurology, plastic and 
reconstructive surgery, cardiology, urology, paediatric surgery, maxillio-facial 
surgery, psychiatry, occupational health and orthopaedics.10
4 Central hospitals: These are the fourth and highest level of healthcare. 
Central hospitals consist of highly specialised units which together provide 
an environment for multi-speciality clinical services, research and 
innovation.10
Source: Health K-NDo. Provincial Hospitals: KwaZulu-Natal Department of Health. 2014 
[cited 2018 Jan 15]. Available from: http://www.kznhealth.gov.za/hospitals.htm10
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included sputum, bronchi alveolar lavage and endotracheal 
aspirates. Overall, S. aureus (24 495, 38.0%) was the most 
frequently isolated pathogen followed by K. pneumoniae 
(14 282, 22.2%), P. aeruginosa (11 231, 17.4%), A. baumannii 
(8010, 12.4%), Enterobacter spp. (4267, 6.6%), E. faecium (2217, 
3.4%) (Table 3 and Figure 1). Similarly, S. aureus (3787, 35.8%) 
and K. pneumoniae (3059, 28.9%) were the most frequently 
isolated species from blood cultures. Gram-negative 
organisms namely K. pneumoniae (2469, 29.2%), A. baumannii 
(2036, 24.1%) and P. aeruginosa (2015, 23.8%) were the most 
common isolates from respiratory samples, followed by 
Gram-positive species, of which S. aureus was the most 
frequently isolated (1353, 16%). K. pneumoniae, a member of 
the Enterobacteriaceae group, was the predominant species 
isolated from urine (4997, 55.5%). Catheters included a 
combination of central venous, arterial and hemodialysis 
catheters. A. baumannii (31.5%), S. aureus (23.4%) and 
K. pneumoniae (23.1%) were the most common isolates 
cultured. Other sample types included wound swabs, pus 
swabs and aspirates. The most frequently isolated species 
from other sample types was S. aureus (18 397, 53.4%).
Antibiotic resistance
During the five-year period, high levels of antibiotic 
resistance were detected among the ESKAPE pathogens. 
Overall, the most common resistance pattern in Gram-
negative ESKAPE pathogens was resistance to amoxicillin-
clavulanate and ceftriaxone. The majority of the A. baumannii 
isolates were resistant to multiple drugs, with over 70% of 
isolates resistant to all tested antimicrobial agents except 
colistin, amikacin and gentamicin. Isolates of P. aeruginosa 
remained fairly susceptible to agents like amikacin, 
piperacillin-tazobactam, meropenem imipenem and colistin. 
Overall, colistin resistance was less than 10% over the five-
year period for the Gram-negative ESKAPE pathogens.
Between 2011 and 2015, 7788 (54.5%) K. pneumoniae isolates 
were resistant to amoxicillin-clavulanate. More than 50% of 
all isolates were resistant to third-generation cephalosporins, 
including ceftriaxone (8326, 58.3%) and ceftazadime (7412, 
51.9%), indicative of ESBL production; 5317 (37.2%) isolates 
were resistant to ciprofloxacin. Of the 14 282 K. pneumoniae 
isolates, 922 (6.4%) were resistant to meropenem (Table 4). 
Increasing antimicrobial resistance trends were observed in K. 
pneumoniae (Figure 2). Resistance to ceftriaxone increased from 
54.6% in 2011 to 65.5% in 2015 (p = 0.018). For the period 2011–
2014 average resistance to ciprofloxacin was 35%, which 
increased to 42% in 2015 (p = 0.015). Resistance to amoxicillin-
clavulanate increased from 50.6% in 2011 and to 62.7% in 2015 
(p = 0.009). Between 2011 and 2014, resistance to meropenem 
was 5% or less. This was followed by a significant increase to 
16% in 2015 (p < 0.001). Colistin resistance in K. pneumoniae was 
approximately 2%, but this was not confirmed by reference or 
molecular methods. Both European Committee on 
Antimicrobial Susceptibility Testing and the Clinical 
Laboratory Standards Institute recommend broth microdilution 
for antimicrobial susceptibility testing of colistin, but broth 
microdilution is rarely used in routine microbiology 
laboratories.12 Broth microdilution is not routinely performed 
at these KwaZulu-Natal public sector microbiology laboratories 
and as a result they may have failed to detect heteroresistance.
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FIGURE 2: Resistance profile of K. pneumoniae (2011–2015). 
TABLE 4: Resistance profiles of Gram-negative ESKAPE pathogens (2011–2015).
Antimicrobial 
agent
Acinetobacter 
baumanni
(8010)
% resistant
Enterobacter spp.
(4267)
% resistant
Klebsiella 
pneumoniae
(14 282)
% resistant
Pseudomonas 
aeruginosa
(11 231)
% resistant
AMC Not tested Not tested 54.50 Not tested
AMK 18 0.75 4.00 6.30
CAZ 77 27.00 51.90 14.20
CIP 71 12.00 37.20 13.40
CRO Not tested Not tested 58.30 Not tested
CST 4.6 2.00 2.00 7.50
GEN 68 17.50 48.00 17.00
IMP 72 3.00 4.00 13.00
MEM 73 2.00 6.40 9.70
TZP 81 22.50 42.00 15.20
AMC, amoxycillin/clavulanic acid; AMK, amikacin; CAZ, ceftazadime; CIP, ciprofloxacin; CRO, 
ceftriaxone; CST, colistin; GEN, gentamicin; IMP, imipenem; MEM, meropenem; TZP, piperacillin/
tazobactam.
TABLE 3: Distribution of ESKAPE pathogens isolated from clinical samples collected in public sector healthcare facilities in KwaZulu-Natal from 2011–2015.
ESKAPE pathogen Blood Respiratory Urine Catheter Other† Total
n % n % n % n % n % n %
A. baumannii 1572 14.9 2036 24.1 894 9.9 637 31.5 2871 8.3 8010 12.4
P. aeruginosa 596 5.6 2015 23.8 910 10.1 224 11.1 7486 21.7 11 231 17.4
S. aureus 3787 35.8 1353 16 484 5.4 474 23.4 18 397 53.4 24 495 38.0
K. pneumoniae 3059 28.9 2469 29.2 4997 55.5 468 23.1 3289 9.5 14 282 22.2
E. faecium 877 8.3 29 0.3 756 8.4 52 2.6 503 1.5 2217 3.4
Enterobacter spp. 678 6.4 558 6.6 955 10.06 170 8.4 1906 5.5 4267 6.6
Total 10 569 100 8460 100 8996 100 2025 100 34 452 100 64 502 100
†, Includes pus swabs, pus and aspirates.
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High MDR rates were observed for A. baumannii with over 70% 
of isolates resistant to meropenem, imipenem, ciprofloxacin, 
piperacillin-tazobactam and ceftazidime (Table 4).
Accumulative average resistance to piperacillin-tazobactam, 
ceftazadime, ciprofloxacin, meropenem, and amikacin 
observed in P. aeruginosa was 1706 (15.2%), 1601 (14.2%), 1501 
(13.4%), 1090 (9.7%) and 716 (6.3%), (p < 0.001) (Table 4). 
Although 840 (7.5%) samples of P. aeruginosa, were resistant 
to colistin, this was not confirmed by reference or molecular 
methods. Over the five-year period, an increase in the total 
number of P. aeruginosa was noted (p = 0.002) (Figure 1). 
During 2013–2015, decreasing trends in resistance patterns 
were observed in P. aeruginosa to ceftazadime (from 17% to 
13%, p = 0.004), piperacillin-tazobactam (from 27% to 21%, 
p < 0.001), meropenem (from 18% to 10%, p < 0.001), 
ciprofloxacin (from 22% to 18%, p = 0.002), and amikacin 
(from 10% to 8%, p < 0.001) (Figure 3).
During the five-year period, the average accumulative 
resistance rate to available carbapenems observed in 
Enterobacter spp. was 5%. Resistance to ciprofloxacin was 
greater in E. cloacae (16%) compared to E. aerogenes (8%) (data 
not shown).
As illustrated in Figure 4, rates of MRSA varied between 18% 
and 31% per year. Overall, a decreasing trend in the 
proportion of MRSA was observed between 2011 and 2014, 
28% to 18% (p < 0.001). Decreasing resistance rates or trends 
across several antibiotic classes, namely gentamicin, 
clindamycin, ciprofloxacin, erythromycin and rifampicin, 
were also noted. No resistance to vancomycin, teicoplanin 
and linezolid was observed. Of the 24 495 isolates of S. aureus 
isolated over the study period, 22 596 (92%) were resistant to 
penicillin, 12 168 (49%) were resistant to co-trimoxazole, 6034 
(24%) were resistant to cloxacillin, 5352 (21.8%) were resistant 
to ciprofloxacin, 4916 (20%) were resistant to erythromycin, 
4702 (19%) were resistant to rifampicin, and 917 (3.7%) were 
resistant to clindamycin. All isolates of E. faecium (2217) were 
susceptible to vancomycin and linezolid.
ESBL-producing K. pneumoniae, increased from 54.9 in 2011 
to 65.5% in 2015 (p = 0.018). MRSA decreased from 31.4% in 
2012 to 19.1% in 2015 (p < 0.001). MDR A. baumanni decreased 
from 85% in 2012 to 70% in 2015 (Figure 5). Overall, during 
the five-year period 6351 (79.2%) of all A. baumannii were 
MDR, 6034 (24.6%) of all S. aureus were MRSA and 8511 
(59.5%) of K. pneumoniae were ESBL-producers.
Discussion
Antimicrobial resistance is now a global pandemic that 
threatens the health, economic and social well-being of 
every individual.13 Antimicrobial resistance among bacterial 
pathogens is increasing globally at a rapid rate, including South 
Africa.14 Data from the Centers for Disease Control and 
Prevention indicate that the six ESKAPE bacteria are responsible 
for two-thirds of all healthcare-associated infections.15 The 
ESKAPE group of pathogens feature among the critical and 
high priority pathogens on the WHO global PPL. In this study, 
we report on five-year surveillance of ESKAPE pathogens and 
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describe the incidence and resistance profiles of the ESKAPE 
pathogens in KwaZulu-Natal, South Africa.
Effective infection prevention and control bundles, 
comprising hand hygiene, contact precautions and a change 
in antibiotic prescription culture, advocated locally and 
internationally may have contributed to the possible decline 
in MRSA rate;16 however, the number of ESBL-producing 
K. pneumoniae increased. Infection prevention and control 
interventions should impact on decreasing both pathogens, 
but a notable increase in the number of ESBL-producing 
K. pneumoniae was observed. The use of third-generation 
cephalosporins, as part of the Integrated Management of 
Childhood Illness Guidelines17 and Sexually Transmitted 
Infections Management Guidelines in South Africa,18 may 
have contributed to the increase in ESBL-producing 
K. pneumoniae. Third-generation cephalosporins are 
administered empirically at the discretion of a community 
centre healthcare professional on suspicion of meningitis, 
sepsis or as part of syndromic management for sexually 
transmitted infections. In our study, the percentage resistance 
of 24% to methicillin observed in S. aureus was lower than the 
46% that was described by Perovic et al., in 2015.16 MRSA 
proportions exceeded 20% in all WHO regions, and in some 
countries it exceeded 80%.1 The epidemiology of MRSA in 
Africa was highlighted in a systematic review of 263 articles. 
Prevalence of MRSA in Africa varied from 12% in Tunisia 
to 82% in Egypt.16 Our findings confirm that vancomycin 
resistance among S. aureus is yet to be encountered in 
KwaZulu-Natal. Decreasing trends in antimicrobial resistance 
to erythromycin, clindamycin, rifampicin and ciprofloxacin 
were observed in S. aureus during the study period. NHLS 
public sector susceptibility data (January–December 2009) 
presented by Crowther et al. showed varying rates of MRSA.19 
The data obtained were from eight laboratories located in 
academic hospitals in South Africa, excluding KwaZulu-
Natal. Rates of cloxacillin resistance in S. aureus varied 
between 24% and 84%. Additionally, clindamycin resistance 
reported in that study varied between 15% and 70% in 
comparison to less than 3% observed in our analysis.
K. pneumoniae was the most common Gram-negative 
organism isolated from the ESKAPE group and during the 
study period K. pneumoniae accounted for almost one-third of 
all ESKAPE organisms isolated from blood. In a 2015 global 
surveillance report by Healthcare-associated Infections 
Surveillance Network and United States National Healthcare 
Safety Network 8.7% and 9.9% of all hospital acquired 
infections were attributable to K. pneumoniae20. A cause for 
concern in this study is the steady increase in antimicrobial 
resistance to amoxicillin-clavulanate and third-generation 
cephalosporins reflecting inhibitor-resistance and ESBL 
production in K. pneumoniae. Perovic et al. reported similar 
proportions of ESBL-producing K. pneumoniae (68.3%) from 
bloodstream infections over a four-year period.21 In another 
South African study, Dramowski et al. reported that 75.7% 
and 78.3% of all K. pneumoniae isolated from paediatric 
community-acquired and hospital-acquired bloodstream 
infections were ESBL producers.22 According to a WHO 
report in 2014, resistance rates of K. pneumoniae to third-
generation cephalosporins varied between 8% and 77% in 
Africa.1 Extended spectrum β-lactamase (ESBL) production 
in Escherichia coli and K. pneumoniae have been reported in 
Thailand (rate between 3.0% and 23.1%), China (65% and 
31.9%), and India (67.0% and 55.0%).23 WHO reported that 
resistance to third-generation cephalosporins observed in 
K. pneumoniae was greater than 30% worldwide and greater 
than 60% in some countries.1
The rise in ciprofloxacin resistant K. pneumoniae in 2015 could 
be due to increased use of ciprofloxacin for treatment of ESBL-
producing K. pneumoniae infections. More significantly, 
ciprofloxacin is used as a first-line therapy for uncomplicated 
urinary tract infections in the South African Standard 
Treatment Guidelines.10 During the period 2010–2012, national 
sentinel site surveillance for antimicrobial resistance in 
K. pneumoniae from South Africa was performed and 46.5% of 
all isolates were resistant to ciprofloxacin.21 Due to the large 
number of quinolone-resistant and ESBL-producing 
K. pneumoniae, treatment for severe K. pneumoniae infections 
rely on carbapenems.24 Perovic et al. noted less than 6% 
resistance rate to carbapenems in K. pneumoniae during 2010–
2012.21 With reference to our study, although resistance to 
carbapenems was generally low between 2011 and 2014, a 
significant increase of 16% was noted in 2015, indicative of an 
emerging problem. Massive surveillance gaps in documenting 
carbapenem-resistant K. pneumoniae from Africa exist and this 
is a great challenge. In 2014, the WHO reported that 0% – 4% 
of K. pneumoniae from Africa were resistant to carbapenems; 
however, these data were obtained from only four countries1 
on the African continent. Increasing carbapenem resistance in 
K. pneumoniae during 2015 could very well represent the 
global trends in increasing resistance of Enterobacteriacae to 
carbapenems. The WHO has highlighted alarming rates of 
carbapenem resistance in K. pneumoniae, exceeding 50% in 
some countries of the eastern Mediterranean and Europe.1 
Limited therapeutic options to treat infections due to 
carbapenem-resistant K. pneumoniae are among the greatest 
challenges facing clinicians. Therapeutic options include 
colistin, but a recent Italian study showed that among 178 
carbapenemase-producing K. pneumoniae isolates from 
different hospitals, 43% were also resistant to colistin.25 
Tigecycline is not available for use in the public healthcare 
sector in KwaZulu-Natal; therefore, susceptibility and 
resistance data for this drug were not analysed in this study. 
The only remaining intervention to prevent dissemination 
of MDR organisms, such as carbapenemase-producing 
K. pneumoniae, is infection control.24
The significant decrease in resistance observed in P. aeruginosa 
to many of the anti-pseudomonal antimicrobial agents may 
be attributed to the fact that the majority of P. aeruginosa 
was isolated from non-sterile sites. It is well known that 
P. aeruginosa is a long-term coloniser and can persist for 
prolonged periods of time; hence, many clinicians opt not 
to administer systemic antimicrobials in a patient who is 
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otherwise clinically well. The emergence and spread of 
antibiotic-resistant Gram-negative pathogens can be 
attributed to antibiotic selective pressure;26 therefore, the 
likelihood of developing MDR P. aeruginosa is reduced when 
no antimicrobials are administered for colonising bacteria.
Greater than 70% rates of resistance were observed in 
A. baumanni for most antimicrobials tested, except gentamicin, 
amikacin and colistin, where resistance was 68%, 18% and 4%, 
respectively. Susceptibility to amikacin and colistin remained 
stable for A. baumannii during the five-year period. The 
propensity for development of resistance to a drug is lower 
when it is used in combination than with monotherapy. This 
could explain the stable susceptibility to amikacin as it is only 
used as part of a dual therapy and never alone in South Africa. 
Colistin susceptibily could be due to its lack of availability or 
restricted use in the public health sector in South Africa. 
A motivation and prior approval is mandatory prior to drug 
administration; hence, most clinicians are unable to access 
the drug. Additionally, in the majority of patients with 
A. baumannii, treatment is not offered as most Acinetobacter 
species are considered long-term colonisers of low virulence 
potential and are intrinsically resistant to all but a few 
antimicrobial agents.27,28 Therapy for these colonisers would 
only lead to the emergence of other MDR organisms. Even in 
the face of directed therapy, Acinetobacter has the ability to 
develop resistance,27 and the isolation of colistin-resistant 
subpopulations of Acinetobacter is of great concern.28 Drawing 
a comparison to the global burden of MDR A. baumannii, a 
recent systemic review and meta-analysis by Bialvaei et al. 
(2017) highlighted that the pooled prevalence of MDR 
A. baumannii was 72% annually, with frequencies of between 
22% and 100%,29 similar to the findings in the present study.
Limitations
There are a number of limitations of this study. The total 
number of samples received by all the laboratories during the 
study period was not available. There were deficiencies in 
data collection for 2014 due to an upgrade of microbiological 
diagnostic systems, resulting in unrecoverable surveillance 
data. Additionally, although this surveillance reflects nine 
hospitals across two districts in KwaZulu-Natal, the private 
health sector was not included, and the results reflect only 
the public health sector in KwaZulu-Natal, South Africa.
Conclusion
This is the first study describing resistance trends in WHO 
global priority pathogens within KwaZulu-Natal. The high 
prevalence rates of antimicrobial resistance observed in 
ESKAPE pathogens signal the need to improve antimicrobial 
stewardship and infection prevention and control 
programmes in the region.
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